Loading stock data…
$0.35-0.02 (-4.89%)
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States.
Neumora Therapeutics, Inc. in the Healthcare sector is trading at $0.35 with a market capitalization of $123M. Wall Street consensus targets $6.14 (7 analysts), implying a +1644.6% move over the next 12 months. The stock is currently near its 52-week low of $0.35, remaining 81.2% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 9 is oversold, raising the odds of a near-term bounce. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$42.19M↑ | -$52.86M↑ | -$58.48M↓ | -$57.70M↓ | -$54.04M |
| Net Income | -$43.08M↑ | -$53.46M↑ | -$59.45M↓ | -$56.76M↓ | -$52.73M |
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant...